	WORKSHEET: Pre-Review		
	NUMBER	DATE	PAGE
	HRP-308	5/1/2022	1 of 2

The purpose of this checklist is to provide support for IRB staff conducting screening of submission materials.

1 ALL REVIEWS

- Determine the laws that apply to the Human Research and indicate in the “Regulatory Oversight” section of the Pre-Review Activity.
- Verify funding information and determine if additional criteria are applicable.
- Determine whether any investigators or research staff are Restricted. If so, notify investigator and provide information to resolve restriction.
- Determine whether investigators have completed education requirements or COI disclosures as required.
- Determine whether the Human Research has received all required ancillary reviews (per HRP-309 -WORKSHEET - Ancillary Review Matrix) and approvals by the appropriate committees and officials.
- If the Human Research could be subject to EU GDPR, send to privacy officer for review.
- If there is a HIPAA authorization, review using HRP-330 - WORKSHEET - HIPAA Authorization
- If a HIPAA waiver of authorization is required, grant using HRP-441 - CHECKLIST - HIPAA Waiver of Authorization
- Determine whether the submission is for a Single-Site Study, Collaborative Study, or Multi-Site Study.
- Note any missing materials necessary for review in the “Missing Materials” section of the Pre-Review Activity:**

- | | |
|---|---|
| <input type="checkbox"/> Application & appendices as applicable) | <input type="checkbox"/> Data collection instruments |
| <input type="checkbox"/> Investigator Protocol | <input type="checkbox"/> Written material to be seen or heard by subjects |
| <input type="checkbox"/> Consent document(s) or script(s) | |
| <input type="checkbox"/> Determine whether any new information has been provided. (For example, a new risk.) If so, follow HRP-024 - SOP - New Information. | |

2 INITIAL REVIEW and MODIFICATION (when the modification affects one of the following)

- If the research involves the use of a drug use the HRP-306 - WORKSHEET - Drugs.
- If the research involves the use of a device use the HRP-307 - WORKSHEET - Devices. Note any special determinations that need to be made by the convened IRB or Designated Reviewer.
- If the device meets the abbreviated IDE requirements, note “Non-significant device determination”.

Note any missing materials necessary for review in the “Missing Materials” section of the Pre-Review Activity:


- | | |
|--|---|
| <input type="checkbox"/> Qualifications of the key personnel | <input type="checkbox"/> Institutional Profile as applicable |
| <input type="checkbox"/> Grant application (optional requirement) | <input type="checkbox"/> Product information for medical devices |
| <input type="checkbox"/> Complete sponsor protocol (including DHHS protocol) | <input type="checkbox"/> For the Department of Education (ED) research ensure that a permission letter has been submitted attesting compliance with FERPA and PPRA. |
| <input type="checkbox"/> DHHS-approved sample consent document | |
| <input type="checkbox"/> Investigator brochure for investigational drug | |
| <input type="checkbox"/> Package insert for marketed drugs | |
| <input type="checkbox"/> Executed Reliance Agreement when required | |

Note missing/inappropriately answered Investigator Protocol sections in the “Missing Materials” section of the Pre-Review Activity:

- | | | | |
|--|---|---|---|
| <input type="checkbox"/> IRB Review History | <input type="checkbox"/> Inclusion/Exclusion Criteria | <input type="checkbox"/> Data Management | <input type="checkbox"/> Consent Process |
| <input type="checkbox"/> Objectives | <input type="checkbox"/> Compensation for Injury | <input type="checkbox"/> Confidentiality | <input type="checkbox"/> Consent Documentation |
| <input type="checkbox"/> Background | <input type="checkbox"/> Local Number of Subjects | <input type="checkbox"/> Provisions to Monitor Data | <input type="checkbox"/> Vulnerable Populations |
| <input type="checkbox"/> Setting | <input type="checkbox"/> Total Number of Subjects | <input type="checkbox"/> Withdrawal of Subjects | <input type="checkbox"/> Drugs or Devices |
| <input type="checkbox"/> Resources Available | <input type="checkbox"/> Study Timelines | <input type="checkbox"/> Risks to Subjects | <input type="checkbox"/> Multi-Site Research |
| <input type="checkbox"/> Prior Approvals | <input type="checkbox"/> Study Endpoints | <input type="checkbox"/> Potential Benefits to Subjects | <input type="checkbox"/> Community-Based |
| <input type="checkbox"/> Study Design | <input type="checkbox"/> Procedures Involved | <input type="checkbox"/> Provisions to Protect Privacy | <input type="checkbox"/> Participatory Research |
| <input type="checkbox"/> Recruitment Methods | <input type="checkbox"/> Data and Specimen Banking | <input type="checkbox"/> Economic Burden to Subjects | <input type="checkbox"/> Sharing of Results |

“Final Contingencies” section of the Pre-Review Activity:

- | | |
|---|---|
| <input type="checkbox"/> Research is subject to regulations not overseen or conducted by the organization | <input type="checkbox"/> There are inadequate provisions to control the device(s) |
| <input type="checkbox"/> Positive financial declaration without a Conflict of Interest report | <input type="checkbox"/> There are inadequate provisions for an investigator held IND |
| <input type="checkbox"/> Protocol information relates to an item in the list of institutional financial interests | <input type="checkbox"/> There are inadequate provisions for an investigator held IDE |
| <input type="checkbox"/> An IND is required and there is no IND | <input type="checkbox"/> External site(s) getting federal funds from the organization does not have a federalwide assurance (FWA) |
| <input type="checkbox"/> An IND is required and there is insufficient documentation | <input type="checkbox"/> The research involves adults unable to consent and statements by the investigator and legal counsel regarding which individuals are legally authorized representatives do not match. |
| <input type="checkbox"/> An IDE/HDE is required and there is no IDE/HDE | <input type="checkbox"/> The research involves children and statements by the investigator and legal counsel regarding which persons do not match. |
| <input type="checkbox"/> An IDE/HDE is required and there is insufficient documentation | |
| <input type="checkbox"/> There are inadequate provisions to control the drug(s) | |

	WORKSHEET: Pre-Review		
	NUMBER	DATE	PAGE
	HRP-308	5/1/2022	2 of 2

3 INITIAL REVIEW and MODIFICATIONS FOR pSITES RELYING ON THIS IRB (when the modification affects one of the following)
<input type="checkbox"/> The site record includes all of the following: <ul style="list-style-type: none"> <input type="checkbox"/> Completed Basic Information Page <input type="checkbox"/> Completed Local Funding Sources Page (if relevant) <input type="checkbox"/> Site Informed Consent Document <input type="checkbox"/> All other documents required by the Study
4 CONTINUING REVIEW
<input type="checkbox"/> If Continuing review is not required, see if the information can be used for the annual Administrative Check-in. <input type="checkbox"/> Note missing Continuing review form in the "Missing Materials" section of the Pre-Review Activity.
5 MODIFICATION
<input type="checkbox"/> Note missing modification form in the "Missing Materials" section of the Pre-Review Activity.
6 STUDY CLOSURE
<input type="checkbox"/> Confirm that the research meets the criteria for closure and note in the Study Closure Section of the Pre-Review Activity.